GenDx Revenue and Competitors

GenDx develops and markets a comprehensive line of In Vitro Diagnostic (IVD) tests and services, anal-ysis software and education. The company is a pioneer in the area of Sanger Based Typing (SBT) for transplantation procedures. Since 2012 Next generation Sequencing (NGS) has been introduced as the latest approach for high resolution typing. Until today, SBT is considered as the golden standard for HLA typing, enabling matching of patients and donors with the highest accuracy possible in the HLA field for stem cell and solid organ transplantation. However, NGS is expected to develop soon as the new golden standard. Extending our portfolio in the area of transplantation and personalised diagnostics, the Chimerism Monitoring product line by qPCR has been added since 2015. Founded in 2005 by Erik Rozemuller, Wietse Mulder and UMC participaties BV., GenDx has long-standing strategic alliances with renowned business partners, providing access to a large global cus-tomer base. GenDx is a privately owned, independent company with experienced management and dedicated employees. First-class customer service, science-based innovation and high ethical standards are shared values that are more than words to GenDx. Our full dedication to quality guarantees excel-lent reliability and performance of GenDx products to our customers and their patients. Therefore, GenDx implemented the ISO 13485:2003 quality system and received CE-IVD clearance for its complete line of HLA-typing products. Cooperating with our global distributors in and beyond the field of tissue typing, GenDx strives to make patients benefit from its unique, personal approach to diagnostics.